Clinical trial
APIXABAN DRUG UTILIZATION STUDY IN STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF)
NCT03441633 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- APIXABAN DRUG UTILIZATION STUDY IN STROKE PREVENTION IN ATRIAL FIBRILLATION (SPAF)
- Lead sponsor
- Pfizer
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 18, 2016
- Completion date
- March 8, 2017
- Enrollment
- 51,690 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.